PENGUKURAN KADAR FIBRINOGEN SEBAGAI PETANDA INFLAMASI SISTEMIK PADA PASIEN PENYAKIT PARU OBSTRUKTIF KRONIK
Abstract
Abstrak
Pendahuluan: peradangan sistemik adalah penanda morbiditas dan mortalitas yang signifikan pada pasien dengan COPD. Fibrinogen merupakan salah satu protein fase akut yang dapat digunakan sebagai penanda inflamasi sistemik dan sindrom metabolik. Penelitian ini dilakukan untuk mengevaluasi kadar fibrinogen pada pasien PPOK stabil.
Metode: Dalam studi cross sectional observasional, fourthy sepertiga pasien PPOK stabil kami mengukur kadar fibrinogen plasma tersebut.
Hasil: Ada 43 pasien PPOK stabil. Rerata usia pada pasien PPOK stabil adalah 63,28 ± 5,595 tahun, FEV1 1238,14 ± 481,3, 54,30 ± 13,9% diprediksi. Tingkat fibrinogen meningkat (rata-rata 364,51 ± 70,09 mg / dl). Tingkat fibrinogen yang berkaitan dengan prediksi FEV1 (r = -, 312, p <0,05) dan frekuensi eksaserbasi.
Kesimpulan: Studi menemukan bahwa tingkat fibrinogen meningkat pada pasien PPOK stabil.
Abstract
Introduction: Systemic inflammation is relevant extrapulmonary markers of morbidity and mortality in patients with COPD. Fibrinogen is one of acute phase protein that can be used as marker of systemic inflammation and metabolic syndrome. This study was undertaken to evaluate the relations fibrinogen level in stable COPD patients.
Methods: In observasional cross sectional study, fourthy-third stable COPD patients we measured the plasma fibrinogen levels.
Results:There were 43 stable COPD patients. The mean of age in stable COPD patients was 63.28±5.595 years, FEV1 1238,14±481,3, 54,30±13,9% predicted. Fibrinogen level was increased (mean 364,51±70,09 mg/dl). Fibrinogen level were related to predicted FEV1 (r=-,312;p<0,05) and frequency of exacerbations.
Conclusion: Study found that fibrinogen level was increased in stable COPD patients.
Keywords
References
Agusti AGN, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effect of chronic obstructive pulmonary disease. Eur Respi J. 2003;21:347-60.
Sin DD, Man SFP. Systemic inflammation and mortality in chronic obstructive pulmonary disease. Can J Physiol Pharmacol. 2007;85:141-7.
MacNee W, Maclay J, McAllister D. Cardiovasculer injury and repair in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5:824-33.
Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a metaanalysis. Thorax. 2004;59:574-80.
Sin DD, Man SFP. Commentary: fueling the fire-systemic inflammation and development of lung disease in the general community. Int J Epid. 2006;35:1108-10.
Global Initiative for Chronic Obstructive Pulmonary Disease. Pathogenesis, pathology and pathophysiology. In: Global strategy for diagnosis management and prevention of Cronic Obstructive Lung Disease. NHLBI Publication;2009.p. 17-39.
Tkac J, Man SF, Sin DD. systemic consequences of COPD. Therapeutic Advances in Respiratory Disease. 2007;1:47-69.
Agusti. Systemic effect of chronic obstructive pulmonary disease, what we know and what we don’t know(but should). Proc Am Thorac Soc. 2007;4:522-5.
Sitompul PA. Hubungan kolonisasi bakteri jalan napas bawah dengan inflamasi, fungsi paru dan klinis pada penyakit paru obstruktif kronik stabil. Tesis bagian Pulmonologi dan Kedokteran Respirasi FKUI. Jakarta 2008.
Watz H, Wasachki B, Kirsten A, Muller KC, Kretschmar G, Meyer T, et al. The metabolic syndrome in patients with chronic bronchitis and COPD. Chest. 2009;136:1039-46.
Groenewegen KH, Postma DS, Hop WCJ, Wielders PLM, Schlosser NJJ, Wouters EF, et al. Increased systemic inflammation is a risk factor for COPD exacerbations. Chest. 2008;133:350-7.
Wiyono WH, Riyadi J, Yunus F, Ratnawati, Prasetyo S. The benefit of pulmonary rehabilititation against quality of life alteration and functional capacity of chronic obstructive pulmonary disease (COPD) patients assessed using St. George Respiratory Questionnaire (SGRQ) and 6 minutes walking distance test (6MWD). Med J Indones. 2006;15:162-72.
Kusmana DA. Profil hipertensi pulmoner pada penyakit paru obstruktif kronik di RS Persahabatan. Tesis bagian Pulmonologi dan Kedokteran Respirasi FKUI. Jakarta 2010.
Dahl M, Hansen AT, Vestbo J, Lange P, Nordestgaard BG. Elevated plasma fibriongen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:1008-11.
Rio FG, Miravitlles M, Soriano JB, Tauleria ED, Sanches G, Sobradillo V, et al. systemic inflammation in chronic obstructive pulmonary disease:population-based study. Respiratory Research. 2010;11:1-15.
MacCallum PK. Marker of hemostasis and systemic inflammation in heart disease and atherosclerosis in smokers. Proc Am Thorac.2005;2:34-43.
Higashimoto Y, Iwata T, Okada M, Satoh H, Fukuda K, Tohda Y. Serum biomarkers as predicter of lung function decline in chronic obstructive pulmonary disease. Respiratory Medicine. 2009;1:1-8.
Tapson VF. The role of smoking in coagulation and thromboembolism in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2:71-7.
Kaczmarek P, Sladek K, Skucha W, Rzeszutso M, Iwaniec T, Dziedzina S, et al. The influence of simvastatin on selected inflammatory markers in patients with chronic obstructive pulmonary disease. Pol Arch Med Wewn. 2010;120:11-7.
Man SF, Sin DD. Effect of corticosteroids on systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc.2005;2:78-82.
Thyagarajan B, Jacobs DR, Apostol GG, Smith LJ, Lewis CE, Williams OD. Plasma fibrinogen and lung function: the CARDIA study. International Journal of Epidemiology. 2006;35:1001-8.
Donaldson GC, Seemungal TA, Patel IS, Bhowmik A, Wilkinson TM, Hurst JR, et al. Airway and systemic inflammation and decline lung function in patients with COPD. Chest.2005;28:1995-2004.